As second-line therapy for PsA and axSpA, no clear treatment-retention benefit at 3 years was seen when swapping to a bDMARD with another MOA.

Large cohort study finds TNF inhibitors linked to lower cancer risk in psoriasis, supporting long-term safety of biologic ...

Juvenile idiopathic arthritis, older age, and concomitant immunomodulation delay the onset of psoriasiform dermatitis in ...

A growing number of women with chronic inflammatory diseases are continuing to use TNF inhibitors throughout pregnancy.

Tapering TNF inhibitors is safe and maintains low disease activity for 2 years in psoriatic arthritis and axial ...

TNF inhibitors have similar rates of adverse events and treatment response in ankylosing spondylitis regardless of whether the disease developed early or late in life, according to data published ...

Treat-to-target tapering of TNF inhibitors in patients with psoriatic arthritis or axial spondyloarthritis does not result in any negative impact on disease activity, compared with the full dose ...

Tumor necrosis factor inhibitor use in patients with IMIDs did not increase the risk of de novo heart failure or worsen existing heart failure.

Whether TNF inhibitors prevent structural damage in ankylosing spondylitis remains a controversial topic, as three prospective trials failed to show any evidence to support this notion. However ...

Early initiation of tumor necrosis factor (TNF) inhibitors in ankylosing spondylitis could increase future risk of cardiovascular disease, according to a new study presented at the American ...

News & Views Published: 11 March 2014 Rheumatoid arthritis When TNF inhibitors fail in RA—weighing up the options Lucia Silva-Fernandez & Kimme Hyrich Nature Reviews Rheumatology 10, 262–264 ...